Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 10 of 10 results for retinitis pigmentosa

  1. Insertion of a subretinal prosthesis system for retinitis pigmentosa (IPG537)

    Evidence-based recommendations on insertion of a subretinal prosthesis system for retinitis pigmentosa. This involves performing a vitrectomy and implanting a microchip underneath the macula using a transscleral, then subretinal approach.

    Interventional procedures guidance
    Published
    16 December 2015
    View recommendations

    Sections for IPG537

  2. Insertion of an epiretinal prosthesis for retinitis pigmentosa (IPG519)

    Evidence-based recommendations on insertion of an epiretinal prosthesis for retinitis pigmentosa. This involves inserting an implant into the eye that receives data from a small camera on the person's glasses and then stimulates healthy cells in the retina to see basic images.

    Interventional procedures guidance
    Published
    26 June 2015
    View recommendations

    Sections for IPG519

  3. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

    Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

    Highly specialised technologies guidance
    Published
    9 October 2019
    View recommendations

    Sections for HST11

  4. NICE encourages further research on insertion of an epiretinal prosthesis for retinitis pigmentosa. Outcomes should include the impact on quality of life and activities of day-to-day living, and durability of implants. NICE may update the guidance on publication of further evidence.

    encourages further research on insertion of an epiretinal prosthesis for retinitis pigmentosa. Outcomes should include the impact on...

    Research recommendation
    Published
    5 October 2015

  5. NICE encourages further research on subretinal prosthesis system for retinitis pigmentosa. Outcomes should include the impact on quality of life and activities of day-to-day living, and durability of implants. NICE may update the guidance on publication of further evidence.

    NICE encourages further research on subretinal prosthesis system for retinitis pigmentosa. Outcomes should include the impact on quality...

    Research recommendation
    Published
    25 January 2016

  6. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592

    Awaiting development [GID-TA11332] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    12 August 2014

  8. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

    Evidence summary
    Published
    28 March 2017

  9. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

    NICE guideline
    Last updated
    11 May 2023
    View recommendations

    Sections for NG18

  10. Research recommendations

    encourages further research on insertion of an epiretinal prosthesis for retinitis pigmentosa. Outcomes should include the impact on...